Nilotinib

ChemicalBook > CAS DataBase List > Nilotinib

Nilotinib for the treatment of chronic myeloid leukemia Mechanism of Action Absorption, Fate, and Excretion Drug Interactions Binding Mode Side effects Clinical evaluation

Product Name: Nilotinib
CAS No.: 641571-10-0
Chemical Name: Nilotinib
Synonyms: Tasigna;AMN 107;Nilotinib-d6;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide;CS-307;Nilotinib;Nilotinibr;Nilotinib &aMp;AMN107; TASIGNA;Nilotinib, >=99%
CBNumber: CB5966228
Molecular Formula: C28H22F3N7O
Formula Weight: 529.52
MOL File: 641571-10-0.mol

Less

Nilotinib Property

Melting point:: 231-233 °C
Density: 1.36
storage temp.: -20°C Freezer
solubility: Soluble in DMSO (up to 50 mg/ml)
form: Beige powder.
color: Off-white
Stability:: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChI: InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChIKey: HHZIURLSWUIHRB-UHFFFAOYSA-N
SMILES: N1(C=C(C)N=C1)C1C=C(C=C(C=1)NC(=O)C1C=CC(C)=C(NC2=NC=CC(C3=CC=CN=C3)=N2)C=1)C(F)(F)F
CAS DataBase Reference: 641571-10-0(CAS DataBase Reference)

Less

Safety

HS Code: 29335990
Hazardous Substances Data: 641571-10-0(Hazardous Substances Data)

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Less

N-Bromosuccinimide Price

Cayman Chemical

Product number: 10010422
Product name: Nilotinib
Purity: ≥95%
Packaging: 5mg
Price: $25
Updated: 2024/03/01

Cayman Chemical

Product number: 10010422
Product name: Nilotinib
Purity: ≥95%
Packaging: 10mg
Price: $37
Updated: 2024/03/01

Cayman Chemical

Product number: 10010422
Product name: Nilotinib
Purity: ≥95%
Packaging: 25mg
Price: $73
Updated: 2024/03/01

Cayman Chemical

Product number: 10010422
Product name: Nilotinib
Purity: ≥95%
Packaging: 50mg
Price: $118
Updated: 2024/03/01

TRC

Product number: N465300
Product name: Nilotinib
Packaging: 10mg
Price: $60
Updated: 2021/12/16

Less

Nilotinib Chemical Properties,Usage,Production

Nilotinib for the treatment of chronic myeloid leukemia

Nilotinib is a novel drug for targeted cancer therapy and belongs to tyrosine kinase inhibitors for the treatment of patients of chronic myelogenous leukemia (CML) which is resistant to the Gleevec (imatinib) with an excellent efficacy. Gleevec is the primary-choice drug developed by Novartis Company for the treatment of chronic myelogenous leukemia (CML) .
Nilotinib is the developed through the improvement of the molecular structure of imatinib with a stronger selectivity on the BCR-ABL kinase activity. The inhibitory effect of nilotinib on the tyrosine kinase is 30 times as high as that of imatinib. It is capable of suppressing the activity of the imatinib-resistant BCR-ABL mutant kinase while also being able to inhibit the activity of KIT and PDGFR kinase.
With administration twice daily, nilotinib can targeted to the Bcr-Abl protein, interact with it and inhibit the emergence of cancer cells containing abnormal chromosomes. Bcr-Abl protein is produced by cells containing the abnormal Philadelphia chromosome. For patients of CML, this protein is considered to be an important factor for causing the excessive proliferation of cancer-causing white blood cells.
Approved Uses:
TASIGNA® (nilotinib) capsules is a prescription medicine used to treat:
Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
Adults with Ph+ CML in chronic phase and accelerated phase who no longer benefit...
https://www.novartis.us

Mechanism of Action

Nilotinib is a selective tyrosine kinase inhibitor active against Bcr-Abl kinase Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. Nilotinib is 30-fold more potent than imatinib.

Absorption, Fate, and Excretion

Nilotinib is rapidly absorbed and reaches its peak concentration in 3 hours. Nilotinib AUC was increased by 82% when given 30 minutes after a high-fat meal compared with a fasting state. Its elimination half-life is approximately 17 hours. It is metabolized by oxidation and hydroxylation as well as undergoing metabolism by CYP3A4. None of the nilotinib metabolites have significant pharmacologic activity.

Drug Interactions

Nilotinib is a competitive inhibitor of cytochrome P-450 (CYP) isoenzymes 3A4, 2C8, 2C9, and 2D6 and has the potential to increase concentrations of drugs metabolized by these enzymes. Nilotinib plasma concentration is increased during concomitant use with potent CYP3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole). Decreased nilotinib plasma concentration occurs during concomitant use with potent CYP3A4 inducers (e.g., dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort). Drugs that increase the pH of the upper gastrointestinal tract may decrease the solubility of nilotinib and reduce its bioavailability. The oral administration of esomeprazole resulted in a 34% reduction in the AUC of nilotinib.

Binding Mode

Both imatinib and nilotinib bind the inactive conformation of ABL, but the latter allows a better topographical fit. As compared to six H-bonds with imatinib， nilotinib makes only four H-bond interactions with the ABL kinase domain, involving the pyridyl N and the backbone amide NHof Met318; the aniline NH and the side chain hydroxyl of Thr315; the amido NH and side chain carboxylate of Glu286; and the amide carbonyl with the backbone NH of the Asp381. The reverse amide group of nilotinib hydrogen bonds to the side chain carboxylate of Glu286 and the backbone NH ofAsp381, similarly to the amide in imatinib as the position of the Glu286 side chain of ABLkinase shifts and twists slightly to interact with the reverse amide. These changes lead to the 4-methylimidazole and the CFs group being highly effective alternative back pocket binders for the N-methylpiperazine group of imatinib. While the basic N-methyl piperazine of imatinib is partially exposed to solvent, forming two H-bonds to the backbone carbonyl group of Ile360 and His361, the methyl-imidazole group and the trifluoromethyl group of nilotinib pack into a unique hydrophobic pocket, making substantial interactions with the ABL kinase domain of the BCR-ABL protein.

Side effects

Nilotinib may cause anemia, neutropenia and thrombocytopenia. Prolonged QT interval and sudden death has occurred. Pruritus, rash, and nausea are common. Also seen with nilotinib are arthralgias and myalgias. Cough has also been associated with nilotinib.

Clinical evaluation

Nilotinib is the other second-generation Abl kinase inhibitor approved for treatment of patients with CML. Nilotinib has increased affinity for the Abl kinase compared with imatinib, binding with an improved topologic fit to the kinase site in its inactive form.Nilotinib is active in chronic and accelerated phase CML patients who have developed resistance to imatinib. As with dasatinib, nilotinib was compared with imatinib in a phase III randomized trial as initial therapy for chronic phase CML patients, with nilotinib achieving higher rates of complete cytogenetic and major molecular responses and with fewer cases of disease progression or clonal evolution in the nilotinib-treated cohorts. Survival outcomes were similar in all arms. Common adverse events with nilotinib included rash, gastrointestinal disturbances (nausea, vomiting, diarrhea), neutropenia, and thrombocytopenia. Pleural effusion and peripheral edema are less common than with dasatinib. In addition, QT prolongation and a risk of pancreatitis are serious side effects of nilotinib.

Description

Chronic myeloid leukemia (CML), a hematological stem-cell disorder, is definitively diagnosed by the detection of the Philadelphia chromosome, a truncated version of chromosome 22 resulting from the reciprocal translocation of chromosomes 9 and 22 induced by a single mutagenic event. The consequence is the juxtaposition of two genes creating a fusion gene BCR-ABL. This gene leads to the translation of a fusion protein with increased tyrosine kinase activity that contributes to the pathogenesis of CML. Targeting the BCR-ABL protein has led to the successful intervention of the disease. Now established as first-line therapy for CML, imatinib was the first selective tyrosine kinase inhibitor of BCR-ABL. Since imatinib only binds to an inactive conformation of the ABL kinase portion, the conformational restrictions contribute to its selectivity.

Chemical Properties

Off-White Solid

Originator

Novartis (Switzerland)

Uses

Nilotinib, an orally active signal transduction inhibitor that selectively inhibits the tyrosine kinase Bcr-Abl, was discovered and developed by Norvartis and was launched for the treatment of chronic myeloid leukemia (CML) in patients with Philadelphia chromosome-positive (Ph+) disease who are resistant or intolerant to imatinib mesilate. Additional clinical trials are currently underway for the treatment of acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs).

Uses

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM.

Uses

Nilotinib-d6, is the labeled analogue of Nilotinib, which might be useful in treatment of chronic myelogenous leukemia.

Definition

ChEBI: Nilotinib is a member of (trifluoromethyl)benzenes, a member of pyrimidines, a member of pyridines, a member of imidazoles, a secondary amino compound and a secondary carboxamide. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and an anticoronaviral agent.

brand name

Tasigna

General Description

Class: non-receptor tyrosine kinase
Treatment: CML
Elimination half-life = 17 h
Protein binding >97.5%

Clinical Use

Tyrosine kinase inhibitor:
Treatment of chronic myelogenous leukaemia (CML)

Synthesis

The first step in the synthesis of nilotinib involves the nucleophilic aromatic substitution of 3-fluoro-5-(trifluoromethyl)benzonitrile with 2-methylimidazole. The nitrile is then hydrolyzed with sodium hydroxide in aqueous dioxane. A Curtius rearrangement employing diphenylphosphoryl azide in tert-butanol affords the tert-butyl carbamate. Deprotection of the Boc group provides the 3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)aniline piece for the convergent synthesis. Construction of the other half begins with the condensation of 3-amino-4- methylbenzoic acid methyl ester with cyanamide in refluxing ethanolic HCl to generate the 3-guanidinobenzoate. An enamino ketone, prepared by a Claisen condensation of 3-acetylpyridine with ethyl formate in the presence of sodium metal in hot toluene, is then cyclized with the guanidine to yield the pyridylpyrimidine. Following saponification of the ethyl ester, the resultant 4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]benzoic acid is finally coupled with the aniline utilizing diethyl cyanophosphate to provide nilotinib.

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: avoid with clarithromycin, rifampicin (concentration reduced) and telithromycin.
Antifungals: avoid with itraconazole, ketoconazole (concentration increased) and voriconazole.
Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
Antivirals: avoid with boceprevir and ritonavir (concentration possibly increased).
Grapefruit juice: avoid concomitant administration.
Avoid concomitant use with other inhibitors or inducers of CYP3A4. Dose alterations may be required.

Metabolism

Nilotinib is metabolised in the liver via oxidation and hydroxylation, in which cytochrome P450 isoenzyme CYP3A4 plays an important role. Most of an oral dose is eliminated unchanged in the faeces within 7 days.

References

1) Weisberg?et al.?(2006),?AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL; Br J. Cancer,?94?1765 2) Verstovsek?et al.?(2006),?Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells; Ann. Neurol.,?75?209

Nilotinib Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Nilotinib Suppliers

Belgium 1 Brazil 1 Canada 5 China 349 Czech Republic 1 Europe 1 France 2 Germany 6 Greece 1 India 27 Italy 1 Poland 1 South Korea 2 The Netherlands 2 United Kingdom 7 United States 56 Global 463

Ark Pharm, Inc.

Tel: 847-367-3680
Fax: 847-367-3681
Email: sales@arkpharminc.com
Country: United States
ProdList: 1670
Advantage: 56

LGM Pharma

Tel: 1-(800)-881-8210
Fax: 615-250-9817
Email: inquiries@lgmpharma.com
Country: United States
ProdList: 2123
Advantage: 70

MedChemexpress LLC

Tel: 021-58955995
Fax: 609-228-5909
Email: sales@medchemexpress.cn
Country: United States
ProdList: 4861
Advantage: 58

AdooQ BioScience, LLC

Tel: +1 (866) 930-6790
Fax: +1 (866) 333-9607
Email: info@adooq.com
Country: United States
ProdList: 2782
Advantage: 58

HBCChem, Inc.

Tel: +1-510-219-6317
Fax: +1-650-486-1361
Email: sales@hbcchem.com
Country: United States
ProdList: 10648
Advantage: 60

Target molecule Corp.

Tel: 857-239-0968
Fax: 857-239-8801
Email: service1@targetmol.com
Country: United States
ProdList: 2559
Advantage: 60

TargetMol Chemicals Inc.

Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Country: United States
ProdList: 32161
Advantage: 58

InvivoChem

Tel: +1-708-310-1919 +1-13798911105
Fax: 708-557-7486
Email: sales@invivochem.cn
Country: United States
ProdList: 6391
Advantage: 58

Cckinase, Inc.

Tel: +1 (732)236-3202
Email: sales@cckinase.com
Country: United States
ProdList: 2738
Advantage: 58

BOC Sciences

Tel: +1-631-485-4226
Fax: 1-631-614-7828
Email: inquiry@bocsci.com
Country: United States
ProdList: 19553
Advantage: 58

Alchem Pharmtech,Inc.

Tel: 8485655694
Email: sales@alchempharmtech.com
Country: United States
ProdList: 63687
Advantage: 58

Protheragen-ING

Tel: +16313385890
Email: info@protheragen-ing.com
Country: United States
ProdList: 3868
Advantage: 58

Aladdin Scientific

Tel: +1-+1(833)-552-7181
Email: sales@aladdinsci.com
Country: United States
ProdList: 57505
Advantage: 58

Aston Chemical

Tel: 13000000000
Email: sales@astonchem.com
Country: United States
ProdList: 1634
Advantage: 58

Alfa Chemistry

Tel
Email: info@alfa-chemistry.com
Country: United States
ProdList: 2344
Advantage: 58

ApexBio Technology

Tel: --
Fax: --
Email: sales@apexbt.com
Country: United States
ProdList: 6251
Advantage: 58

Alfa Chemistry

Tel: --
Fax: --
Email: info@Alfa-Chemistry.com
Country: United States
ProdList: 6814
Advantage: 0

CarboMer, Inc.

Tel: --
Fax: --
Email: sales@carbomer.com
Country: United States
ProdList: 4026
Advantage: 67

Focus Biomolecules

Tel: --
Fax: --
Email: sales@focusbiomolecules.com
Country: United States
ProdList: 1284
Advantage: 58

Cayman Chemical Company

Tel: --
Fax: --
Email: cayman@caymanchem.com
Country: United States
ProdList: 6213
Advantage: 81

Fluorochem Ltd.

Tel: --
Fax: --
Email: enquiries@fluorochem.co.uk
Country: United States
ProdList: 4583
Advantage: 58

TOPCHEM PHARMACEUTICALS LTD

Tel: --
Fax: --
Email: Vinchem@vinchem.com
Country: United States
ProdList: 140
Advantage: 58

Combi-Blocks, Inc.

Tel: --
Fax: --
Email: les@combi-blocks.com
Country: United States
ProdList: 2555
Advantage: 58

Kare Bay Biochem Inc.

Tel: --
Fax: --
Email: product@karebaybio.com
Country: United States
ProdList: 110
Advantage: 58

2A Biotech USA

Tel: --
Fax: --
Email: info@2abiotech.com
Country: United States
ProdList: 1785
Advantage: 58

MedKoo Biosciences, Inc.

Tel: --
Fax: --
Email: sales@medkoo.com
Country: United States
ProdList: 126
Advantage: 58

Selleck Chemicals LLC

Tel: --
Fax: --
Email: sales@selleckchem.com
Country: United States
ProdList: 1848
Advantage: 58

Barath Biosciences, Inc.

Tel: --
Fax: --
Email: barath@barathbiosciences.com
Country: United States
ProdList: 203
Advantage: 58

Parchem Fine & Specialty Chemicals

Tel: --
Fax: --
Email: info@parchem.com
Country: United States
ProdList: 1031
Advantage: 58

eNovation Chemicals LLC

Tel: --
Fax: --
Email: ales@eNovationChem.com
Country: United States
ProdList: 1673
Advantage: 58

VWR International, LLC.

Tel: --
Fax: --
Email: @sargentwelch.com
Country: United States
ProdList: 6262
Advantage: 58

Oakwood Products, Inc.

Tel: --
Fax: --
Email: sales@oakwoodchemical.com
Country: United States
ProdList: 6193
Advantage: 74

HBCChem Inc.

Tel: --
Fax: --
Email: sales@hbcchem-inc.com
Country: United States
ProdList: 4569
Advantage: 30

Ontario Chemicals, Inc

Tel: --
Fax: --
Email: info@ontariochem.com
Country: United States
ProdList: 723
Advantage: 50

OChem Incorporation

Tel: --
Fax: --
Email: sales@ocheminc.com
Country: United States
ProdList: 6501
Advantage: 60

ACIC Fine Chemicals Inc.

Tel: --
Fax: --
Email: sales@acic.com
Country: United States
ProdList: 492
Advantage: 48

United States Biological

Tel: --
Fax: --
Email: chemicals@usbio.net
Country: United States
ProdList: 6214
Advantage: 80

LC Laboratories

Tel: --
Fax: --
Email: custserv@lclabs.com
Country: United States
ProdList: 503
Advantage: 50

Creative Enzymes

Tel: --
Fax: --
Email: info@creative-enzymes.com
Country: United States
ProdList: 6057
Advantage: 58

Combi-Blocks Inc.

Tel: --
Fax: --
Email: sales@combi-blocks.com
Country: United States
ProdList: 6618
Advantage: 69

Axon Medchem LLC

Tel: --
Fax: --
Email: info@axonmedchem.com
Country: United States
ProdList: 763
Advantage: 58

Matrix Scientific

Tel: --
Fax: --
Email: sales@matrixscientific.com
Country: United States
ProdList: 6632
Advantage: 80

ChemieTek

Tel: --
Fax: --
Email: info@chemietek.com
Country: United States
ProdList: 219
Advantage: 50

Molcan Corporation

Tel: --
Fax: --
Email: info@molcan.com
Country: United States
ProdList: 686
Advantage: 60

SynFine Research

Tel: --
Fax: --
Email: research@synfine.com
Country: United States
ProdList: 1024
Advantage: 68

Focus Synthesis LLC

Tel: --
Fax: --
Email: acd@focussynthesis.com
Country: United States
ProdList: 2487
Advantage: 61

Selleck Chemicals LLC

Tel: --
Fax: --
Email: info@selleckchem.com
Country: United States
ProdList: 824
Advantage: 60

LKT Laboratories, Inc.

Tel: --
Fax: --
Email: info@lktlabs.com
Country: United States
ProdList: 2164
Advantage: 64

AK Scientific, Inc.

Tel: --
Fax: --
Email: sales@aksci.com
Country: United States
ProdList: 6347
Advantage: 65

Tecoland Corporation

Tel: --
Fax: --
Email: info@tecoland.com
Country: United States
ProdList: 275
Advantage: 50

Less

View Lastest Price from Nilotinib manufacturers

Baoji Guokang Bio-Technology Co., Ltd.

Product: Nilotinib 641571-10-0
Price: US $3500.00/ASSAYS
Min. Order: 500g/Bag
Purity: 99%
Supply Ability: 100KG
Release date: 2021-06-07

WUHAN FORTUNA CHEMICAL CO., LTD

Product: Nilotinib 641571-10-0
Price: US $0.00/Kg/Bag
Min. Order: 10g
Purity: 99%min
Supply Ability: 5000g
Release date: 2021-11-03

Nanjing Fred Technology Co., Ltd

Product: Nilotinib 641571-10-0
Price: US $0.00-0.00/kg
Min. Order: 1kg
Purity: 99%，single impurity＜0.1
Supply Ability: 1 ton
Release date: 2023-12-20

641571-10-0, NilotinibRelated Search:

Kresoxim-methyl 3-Aminopyridine EC 2.6.1.2 Bensulfuron methyl Acetaminophen Nilotinib-d6 Nilotinib Hydrochloride Monohydrate Lapatinib Methyl cellulose Methyl acrylate Methylparaben METSULFURON METHYL 2-Aminopyridine 4-Dimethylaminopyridine Methanol Methyl Nilotinib N-Oxide Nilotinib Impurity 4

Nilotinib

AMN 107

Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-

4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide

Nilotinib(TINIBS )

4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide

4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Nilotinib & its intermediates

Nilotinib for research

Tasigna

CS-307

Nilotinib(AMN 107)

Nilotinib, AMN107, Tasigna

TASIGNA NILOTINIB

Nilotinib-d6

AMN107; TASIGNA

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimid

Nilotinib &aMp

4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Nilotinib (AMN-107)

Nilotinib 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide

Nilotinib, >=99%

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyri

TASIGNA;AMN-107;AMN107

Nilotinib USP/EP/BP

Nilotinibr

NilotinibQ: What is Nilotinib Q: What is the CAS Number of Nilotinib Q: What is the storage condition of Nilotinib

4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide

4-Methyl-N-[3-(4-Methyl-1H-Imidazol-1-yl)-5- (Tri?uoromethyl) Phenyl]-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino] Benzamide

N - [3- (4-methyl-1-imidazolyl) -5-trifluoromethylphenyl] -3- [[4- (3-pyridyl) -2-pyrimidinyl] amino] -4-methylbenzamide

641571-10-0

C28H22F3N7O

AMN-107

Cardiovascular APIs

Inhibitors

API

Molecular Targeted Antineoplastic

Nucleotides and Nucleosides

Bases & Related Reagents

Intermediates & Fine Chemicals

Nucleotides

Pharmaceuticals

Pharmaceutical intermediate